Hematologic Malignancy
Mature B-Cell Non-Hodgkin Lymphoma
CI-CAN-00003259Explore in graph →
Hematologic792 active trials17 approved drugs43 evidence items
- NCIt
- C7056
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00003259Explore in graph →
Clinical trials
2,506 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (393)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06832228 | Study of Pomalidomide Combination with Rituximab and Anti-PD-1 Antibody (PPR) in Third or Later Line Therapy of DLBCL | unknown | N/A | 30 | Zhejiang Cancer HospitalOTHER | 1 | Feb 18, 2025 | clinicaltrials |
| NCT04097067 | ISRT 20 Gy for Indolent Localized Gastrointestinal (GI)-Lymphoma | unknown | N/A | 83 | University Hospital MuensterOTHER | 1 | Aug 27, 2024 | clinicaltrials |
| NCT05284825 |
| A Phase II Trial of Intermediate Radiation Dose For Lymphoma |
| unknown |
| N/A |
| 27 |
| Sunnybrook Health Sciences CentreOTHER |
| 1 |
| Feb 15, 2024 |
| clinicaltrials |
| NCT03121456 | 18F-FDG PET Scan and MRI Diffusion.Evaluation of the Early Therapeutic Response of Diffuse Large B-cell Lymphoma(LYMPHODTECT) | unknown | N/A | 74 | Centre Antoine LacassagneOTHER | 1 | Nov 13, 2023 | clinicaltrials |
| NCT05990985 | The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission. | unknown | N/A | 20 | The First Hospital of Jilin UniversityOTHER | 1 | Aug 18, 2023 | clinicaltrials |
| NCT05863845 | Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCL | unknown | N/A | 52 | Ruijin HospitalOTHER | 0 | May 18, 2023 | clinicaltrials |
| NCT05809180 | Pro-miniCHOP-like Regimen for Treatment-naive Elderly Patients | unknown | N/A | 35 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Apr 20, 2023 | clinicaltrials |
| NCT05784987 | R-MINE+X in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | unknown | N/A | 60 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Mar 27, 2023 | clinicaltrials |
| NCT05777369 | R-CMOP in Patients With Primary Diffuse Large B-cell Lymphoma | unknown | N/A | 30 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Mar 21, 2023 | clinicaltrials |
| NCT05269914 | Safety, Efficacy and Pharmacokinetics of XKDCT023 in DLBCL | unknown | N/A | 10 | The Affiliated Hospital of Qingdao UniversityOTHER | 0 | Mar 8, 2022 | clinicaltrials |
| NCT04914143 | the Effect of Broken Ganoderma Lucidum Spore Powder on Quality of Life and Immune Function in Patients With Diffuse Large B-cell Lymphoma After Chemotherapy | unknown | N/A | 120 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jun 4, 2021 | clinicaltrials |
| NCT04432402 | Lenalidomide in Combination With R-GemOx in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma | unknown | N/A | 124 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jun 16, 2020 | clinicaltrials |
| NCT04154228 | Non-invasive Evaluation of Lymphoma Patients Based on Artificial Intelligence and PET/MRI | unknown | N/A | 100 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 0 | Nov 6, 2019 | clinicaltrials |
| NCT03022123 | The Study of Pegylated Liposomal Doxorubicin Contrast Epirubicin for the Treatment of Diffuse Large B-cell Lymphoma | unknown | N/A | 270 | Hebei Medical University Fourth HospitalOTHER | 1 | Jan 16, 2017 | clinicaltrials |
| NCT01864889 | Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19(CART19) | unknown | N/A | 12 | Chinese PLA General HospitalOTHER | 1 | Jan 28, 2016 | clinicaltrials |
Data updated 22 days agoSource updated Feb 18, 2025source: clinicaltrials